Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=95 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Oral Cavity
Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2
Phase 2 N=69 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Phase 2 N=48 Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma, Head and Neck
Primary: Tumor Response Rate (TRR) — 3; 0 Participants
Phase 2 N=28 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Phase 2 N=26 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Cancer Metastatic
Primary: Safety as Measured by Number of Participants With Drug-related Adverse Events — 19; 2 Participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=12 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants
Phase 2 N=65 Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary: Percentage of Participants With Overall Response Rate — 34.5; 29 percentage of participants
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 2 N=67 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Phase 2 N=66 A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Phase 2 N=5 Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients
Phase 1 N=14 Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck · Carcinoma of the Head and Neck
Primary: Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling — 0; 4; 0; 0 Lymph Nodes
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 2 N=425 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup — 13.2; 18.3 percentage of participants — p=0.2897
Phase 2 N=46 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
Cancer of Head · Cancer of Head and Neck · Cancer of Neck
Primary: Probability of Progression-free Survival (PFS) at 2 Years — 70 percentage of participants
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Phase 2 N=52 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
Phase 2 N=33 Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria — 36.4 percentage of participants
Phase 2 N=14 Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
Neoplasms, Head and Neck
Primary: Number of Participants Achieving Best Overall Response — 7; 3; 1 Participants
Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Phase 2 N=113 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 2 N=34 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Phase 2 N=40 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Carcinoma, Squamous Cell of Head and Neck · Oropharynx Squamous Cell Carcinoma
Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants